FDA OKs Vascular Architects' clinical trial:
This article was originally published in Clinica
Vascular Architects has received a conditional approval from the US FDA to begin a multicentre clinical trial to test its aSpire covered stent as a treatment of superficial femoral and popliteal artery stenoses and occlusions. The VALIANT trial is a prospective, non-randomised study that will enrol up to 100 patients at 10 centres. It will assess the San Jose, California firm's stent and controlled expansion delivery system in patients in whom angioplasty has failed or produced suboptimal results. The stent and delivery system is already cleared in the US and in Europe for treating tracheobronchial strictures and peripheral vascular disease, respectively.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.